Selective Pressure of a Quinoxaline Nonnucleoside Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase (RT) on HIV-1 Replication Results in the Emergence of Nucleoside RT-Inhibitor-Specific (RT Leu-74 → Val or Ile and Val-75 → Leu or Ile) HIV-1 mutants
The quinoxaline nonnucleoside RT inhibitor (NNRTI) (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthio-methyl)-3, 4-dihydroquinoxaline-2(1H)-thione (HBY 097) was used to select for drug-resistant HIV-1 variants in vitro. The viruses first developed mutations affecting the NNRTI-binding pocket, and five...
Gespeichert in:
Veröffentlicht in: | Proceedings of the National Academy of Sciences - PNAS 1996-01, Vol.93 (1), p.34-38 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 38 |
---|---|
container_issue | 1 |
container_start_page | 34 |
container_title | Proceedings of the National Academy of Sciences - PNAS |
container_volume | 93 |
creator | Kleim, Jörg-Peter Rösner, Manfred Winkler, Irvin Paessens, Arno Kirsch, Reinhard Hsiou, Yu Arnold, Edward Riess, Günther |
description | The quinoxaline nonnucleoside RT inhibitor (NNRTI) (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthio-methyl)-3, 4-dihydroquinoxaline-2(1H)-thione (HBY 097) was used to select for drug-resistant HIV-1 variants in vitro. The viruses first developed mutations affecting the NNRTI-binding pocket, and five of six strains displayed the RT G190→ E substitution, which is characteristic for HIV-1 resistance against quinoxalines. In one variant, a new mutant (G190→ Q) most likely evolved from preexisting G190→ E mutants. The negative charge introduced by the G190→ E substitution was maintained at that site of the pocket by simultaneous selection for V179→ D together with G190→ Q. After continued exposure to the drug, mutations at positions so far known to be specific for resistance against nucleoside RT inhibitors (NRTIs) (L74→ V/I and V75→ L/I) were consistently detected in all cultures. The inhibitory activities of the cellular conversion product of 2′,3′-dideoxyinosine (ddI, didanosine), 2′,3′-dideoxyadenosine (ddA) and of 2′,3′-didehydro-3$ ^{\prime}$-deoxythymidine (d4T, stavudine) against these late-passage viruses were shown to be enhanced with the L74→ V/I RT mutant virus as compared with the wild-type (wt) HIV-1MNisolate. Clonal analysis proved linkage of the codon 74 and codon 75 mutations to the NNRTI-specific mutations in all RT gene fragments. The nonnucleoside- and nucleoside-resistance mutation sites are separated by approximately 35 angstrom. We propose that the two sites ``communicate'' through the template-primer which is situated in the DNA-binding cleft between these two sites. Quinoxalines cause high selective pressure on HIV-1 replication in vitro; however, the implication of these findings for the treatment of HIV-1 infection has yet to be determined. |
doi_str_mv | 10.1073/pnas.93.1.34 |
format | Article |
fullrecord | <record><control><sourceid>jstor_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_40173</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>38305</jstor_id><sourcerecordid>38305</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-777b20c3d64cbde69ded3b04561a71c7c6fb86141c18d8c0bd0886d5cbbd5fff3</originalsourceid><addsrcrecordid>eNqFks1u1DAURgMClVLYsSpC8gKhjkQGe5zEicQGVYUZqSowHbq1HOemdeU4wT9V5wV4AB6RJ8HTCQMsECvLPue7-iTfJHlG8JRgRt8MRrhpRadkSrP7yT7BFUmLrMIPkn2MZywts1n2KHns3DXGuMpLvJfslXk-K2i2f-_wHDRIr24AfbLgXLCA-hYJ9Dko098KrQygs96YIDX0TjWAFuZK1cr3diPOQycMWnRdMH0DrZIKjFyjC2WDQ6v1AIigo_niIiUTtIQbsA7QygrjpFWDF_F2tFxNUG_QnRSdQSspvIovS3BBe4eUQf4K0EkH9jJOvyt49rvPcpXuKqXnA0gVa2zGolMIKcvQj2_f0YXQKDZeaEDCNJtryvI7EqWRTMYOXfDCePckedgK7eDpeB4kX96frI7n6enHD4vjd6epzFjhU8ZYPcOSNkUm6waKqoGG1jjLCyIYkUwWbV0WJCOSlE0pcd3gsiyaXNZ1k7dtSw-St9u5Q6g7aCQYb4Xmg1WdsGveC8X_JkZd8cv-hmeYMBrjr8a47b8GcJ53yknQWhjog-OMVcUsp-y_ImEYM0zyKL7eitL2zllod10I5puV45uV4xXlhNMs6i_-7L-Txx2L_OXIN6lfdEzzNmjt4dZH7fm_tUgPt_TaxW_eYVpSnNOfnR31iQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17007015</pqid></control><display><type>article</type><title>Selective Pressure of a Quinoxaline Nonnucleoside Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase (RT) on HIV-1 Replication Results in the Emergence of Nucleoside RT-Inhibitor-Specific (RT Leu-74 → Val or Ile and Val-75 → Leu or Ile) HIV-1 mutants</title><source>Jstor Complete Legacy</source><source>MEDLINE</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Kleim, Jörg-Peter ; Rösner, Manfred ; Winkler, Irvin ; Paessens, Arno ; Kirsch, Reinhard ; Hsiou, Yu ; Arnold, Edward ; Riess, Günther</creator><creatorcontrib>Kleim, Jörg-Peter ; Rösner, Manfred ; Winkler, Irvin ; Paessens, Arno ; Kirsch, Reinhard ; Hsiou, Yu ; Arnold, Edward ; Riess, Günther</creatorcontrib><description>The quinoxaline nonnucleoside RT inhibitor (NNRTI) (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthio-methyl)-3, 4-dihydroquinoxaline-2(1H)-thione (HBY 097) was used to select for drug-resistant HIV-1 variants in vitro. The viruses first developed mutations affecting the NNRTI-binding pocket, and five of six strains displayed the RT G190→ E substitution, which is characteristic for HIV-1 resistance against quinoxalines. In one variant, a new mutant (G190→ Q) most likely evolved from preexisting G190→ E mutants. The negative charge introduced by the G190→ E substitution was maintained at that site of the pocket by simultaneous selection for V179→ D together with G190→ Q. After continued exposure to the drug, mutations at positions so far known to be specific for resistance against nucleoside RT inhibitors (NRTIs) (L74→ V/I and V75→ L/I) were consistently detected in all cultures. The inhibitory activities of the cellular conversion product of 2′,3′-dideoxyinosine (ddI, didanosine), 2′,3′-dideoxyadenosine (ddA) and of 2′,3′-didehydro-3$ ^{\prime}$-deoxythymidine (d4T, stavudine) against these late-passage viruses were shown to be enhanced with the L74→ V/I RT mutant virus as compared with the wild-type (wt) HIV-1MNisolate. Clonal analysis proved linkage of the codon 74 and codon 75 mutations to the NNRTI-specific mutations in all RT gene fragments. The nonnucleoside- and nucleoside-resistance mutation sites are separated by approximately 35 angstrom. We propose that the two sites ``communicate'' through the template-primer which is situated in the DNA-binding cleft between these two sites. Quinoxalines cause high selective pressure on HIV-1 replication in vitro; however, the implication of these findings for the treatment of HIV-1 infection has yet to be determined.</description><identifier>ISSN: 0027-8424</identifier><identifier>EISSN: 1091-6490</identifier><identifier>DOI: 10.1073/pnas.93.1.34</identifier><identifier>PMID: 8552634</identifier><language>eng</language><publisher>United States: National Academy of Sciences of the United States of America</publisher><subject>AIDS/HIV ; Amino acids ; Antiviral Agents - pharmacology ; Base Sequence ; Biochemistry ; Codons ; DNA Primers - chemistry ; Drug Resistance, Microbial ; Enzymes ; Genetic mutation ; HIV 1 ; HIV Reverse Transcriptase ; HIV-1 - growth & development ; human immunodeficiency virus 1 ; Inhibitory concentration 50 ; Molecular Sequence Data ; Mutation ; Nucleosides ; Quinoxalines ; Reverse Transcriptase Inhibitors - pharmacology ; RNA-Directed DNA Polymerase - genetics ; Selection, Genetic ; Virus Replication - drug effects ; Viruses</subject><ispartof>Proceedings of the National Academy of Sciences - PNAS, 1996-01, Vol.93 (1), p.34-38</ispartof><rights>Copyright 1996 National Academy of Sciences</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-777b20c3d64cbde69ded3b04561a71c7c6fb86141c18d8c0bd0886d5cbbd5fff3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.pnas.org/content/93/1.cover.gif</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/38305$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/38305$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,723,776,780,799,881,27901,27902,53766,53768,57992,58225</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8552634$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kleim, Jörg-Peter</creatorcontrib><creatorcontrib>Rösner, Manfred</creatorcontrib><creatorcontrib>Winkler, Irvin</creatorcontrib><creatorcontrib>Paessens, Arno</creatorcontrib><creatorcontrib>Kirsch, Reinhard</creatorcontrib><creatorcontrib>Hsiou, Yu</creatorcontrib><creatorcontrib>Arnold, Edward</creatorcontrib><creatorcontrib>Riess, Günther</creatorcontrib><title>Selective Pressure of a Quinoxaline Nonnucleoside Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase (RT) on HIV-1 Replication Results in the Emergence of Nucleoside RT-Inhibitor-Specific (RT Leu-74 → Val or Ile and Val-75 → Leu or Ile) HIV-1 mutants</title><title>Proceedings of the National Academy of Sciences - PNAS</title><addtitle>Proc Natl Acad Sci U S A</addtitle><description>The quinoxaline nonnucleoside RT inhibitor (NNRTI) (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthio-methyl)-3, 4-dihydroquinoxaline-2(1H)-thione (HBY 097) was used to select for drug-resistant HIV-1 variants in vitro. The viruses first developed mutations affecting the NNRTI-binding pocket, and five of six strains displayed the RT G190→ E substitution, which is characteristic for HIV-1 resistance against quinoxalines. In one variant, a new mutant (G190→ Q) most likely evolved from preexisting G190→ E mutants. The negative charge introduced by the G190→ E substitution was maintained at that site of the pocket by simultaneous selection for V179→ D together with G190→ Q. After continued exposure to the drug, mutations at positions so far known to be specific for resistance against nucleoside RT inhibitors (NRTIs) (L74→ V/I and V75→ L/I) were consistently detected in all cultures. The inhibitory activities of the cellular conversion product of 2′,3′-dideoxyinosine (ddI, didanosine), 2′,3′-dideoxyadenosine (ddA) and of 2′,3′-didehydro-3$ ^{\prime}$-deoxythymidine (d4T, stavudine) against these late-passage viruses were shown to be enhanced with the L74→ V/I RT mutant virus as compared with the wild-type (wt) HIV-1MNisolate. Clonal analysis proved linkage of the codon 74 and codon 75 mutations to the NNRTI-specific mutations in all RT gene fragments. The nonnucleoside- and nucleoside-resistance mutation sites are separated by approximately 35 angstrom. We propose that the two sites ``communicate'' through the template-primer which is situated in the DNA-binding cleft between these two sites. Quinoxalines cause high selective pressure on HIV-1 replication in vitro; however, the implication of these findings for the treatment of HIV-1 infection has yet to be determined.</description><subject>AIDS/HIV</subject><subject>Amino acids</subject><subject>Antiviral Agents - pharmacology</subject><subject>Base Sequence</subject><subject>Biochemistry</subject><subject>Codons</subject><subject>DNA Primers - chemistry</subject><subject>Drug Resistance, Microbial</subject><subject>Enzymes</subject><subject>Genetic mutation</subject><subject>HIV 1</subject><subject>HIV Reverse Transcriptase</subject><subject>HIV-1 - growth & development</subject><subject>human immunodeficiency virus 1</subject><subject>Inhibitory concentration 50</subject><subject>Molecular Sequence Data</subject><subject>Mutation</subject><subject>Nucleosides</subject><subject>Quinoxalines</subject><subject>Reverse Transcriptase Inhibitors - pharmacology</subject><subject>RNA-Directed DNA Polymerase - genetics</subject><subject>Selection, Genetic</subject><subject>Virus Replication - drug effects</subject><subject>Viruses</subject><issn>0027-8424</issn><issn>1091-6490</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks1u1DAURgMClVLYsSpC8gKhjkQGe5zEicQGVYUZqSowHbq1HOemdeU4wT9V5wV4AB6RJ8HTCQMsECvLPue7-iTfJHlG8JRgRt8MRrhpRadkSrP7yT7BFUmLrMIPkn2MZywts1n2KHns3DXGuMpLvJfslXk-K2i2f-_wHDRIr24AfbLgXLCA-hYJ9Dko098KrQygs96YIDX0TjWAFuZK1cr3diPOQycMWnRdMH0DrZIKjFyjC2WDQ6v1AIigo_niIiUTtIQbsA7QygrjpFWDF_F2tFxNUG_QnRSdQSspvIovS3BBe4eUQf4K0EkH9jJOvyt49rvPcpXuKqXnA0gVa2zGolMIKcvQj2_f0YXQKDZeaEDCNJtryvI7EqWRTMYOXfDCePckedgK7eDpeB4kX96frI7n6enHD4vjd6epzFjhU8ZYPcOSNkUm6waKqoGG1jjLCyIYkUwWbV0WJCOSlE0pcd3gsiyaXNZ1k7dtSw-St9u5Q6g7aCQYb4Xmg1WdsGveC8X_JkZd8cv-hmeYMBrjr8a47b8GcJ53yknQWhjog-OMVcUsp-y_ImEYM0zyKL7eitL2zllod10I5puV45uV4xXlhNMs6i_-7L-Txx2L_OXIN6lfdEzzNmjt4dZH7fm_tUgPt_TaxW_eYVpSnNOfnR31iQ</recordid><startdate>19960109</startdate><enddate>19960109</enddate><creator>Kleim, Jörg-Peter</creator><creator>Rösner, Manfred</creator><creator>Winkler, Irvin</creator><creator>Paessens, Arno</creator><creator>Kirsch, Reinhard</creator><creator>Hsiou, Yu</creator><creator>Arnold, Edward</creator><creator>Riess, Günther</creator><general>National Academy of Sciences of the United States of America</general><general>National Acad Sciences</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TM</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19960109</creationdate><title>Selective Pressure of a Quinoxaline Nonnucleoside Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase (RT) on HIV-1 Replication Results in the Emergence of Nucleoside RT-Inhibitor-Specific (RT Leu-74 → Val or Ile and Val-75 → Leu or Ile) HIV-1 mutants</title><author>Kleim, Jörg-Peter ; Rösner, Manfred ; Winkler, Irvin ; Paessens, Arno ; Kirsch, Reinhard ; Hsiou, Yu ; Arnold, Edward ; Riess, Günther</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-777b20c3d64cbde69ded3b04561a71c7c6fb86141c18d8c0bd0886d5cbbd5fff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>AIDS/HIV</topic><topic>Amino acids</topic><topic>Antiviral Agents - pharmacology</topic><topic>Base Sequence</topic><topic>Biochemistry</topic><topic>Codons</topic><topic>DNA Primers - chemistry</topic><topic>Drug Resistance, Microbial</topic><topic>Enzymes</topic><topic>Genetic mutation</topic><topic>HIV 1</topic><topic>HIV Reverse Transcriptase</topic><topic>HIV-1 - growth & development</topic><topic>human immunodeficiency virus 1</topic><topic>Inhibitory concentration 50</topic><topic>Molecular Sequence Data</topic><topic>Mutation</topic><topic>Nucleosides</topic><topic>Quinoxalines</topic><topic>Reverse Transcriptase Inhibitors - pharmacology</topic><topic>RNA-Directed DNA Polymerase - genetics</topic><topic>Selection, Genetic</topic><topic>Virus Replication - drug effects</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kleim, Jörg-Peter</creatorcontrib><creatorcontrib>Rösner, Manfred</creatorcontrib><creatorcontrib>Winkler, Irvin</creatorcontrib><creatorcontrib>Paessens, Arno</creatorcontrib><creatorcontrib>Kirsch, Reinhard</creatorcontrib><creatorcontrib>Hsiou, Yu</creatorcontrib><creatorcontrib>Arnold, Edward</creatorcontrib><creatorcontrib>Riess, Günther</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kleim, Jörg-Peter</au><au>Rösner, Manfred</au><au>Winkler, Irvin</au><au>Paessens, Arno</au><au>Kirsch, Reinhard</au><au>Hsiou, Yu</au><au>Arnold, Edward</au><au>Riess, Günther</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Selective Pressure of a Quinoxaline Nonnucleoside Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase (RT) on HIV-1 Replication Results in the Emergence of Nucleoside RT-Inhibitor-Specific (RT Leu-74 → Val or Ile and Val-75 → Leu or Ile) HIV-1 mutants</atitle><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle><addtitle>Proc Natl Acad Sci U S A</addtitle><date>1996-01-09</date><risdate>1996</risdate><volume>93</volume><issue>1</issue><spage>34</spage><epage>38</epage><pages>34-38</pages><issn>0027-8424</issn><eissn>1091-6490</eissn><abstract>The quinoxaline nonnucleoside RT inhibitor (NNRTI) (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthio-methyl)-3, 4-dihydroquinoxaline-2(1H)-thione (HBY 097) was used to select for drug-resistant HIV-1 variants in vitro. The viruses first developed mutations affecting the NNRTI-binding pocket, and five of six strains displayed the RT G190→ E substitution, which is characteristic for HIV-1 resistance against quinoxalines. In one variant, a new mutant (G190→ Q) most likely evolved from preexisting G190→ E mutants. The negative charge introduced by the G190→ E substitution was maintained at that site of the pocket by simultaneous selection for V179→ D together with G190→ Q. After continued exposure to the drug, mutations at positions so far known to be specific for resistance against nucleoside RT inhibitors (NRTIs) (L74→ V/I and V75→ L/I) were consistently detected in all cultures. The inhibitory activities of the cellular conversion product of 2′,3′-dideoxyinosine (ddI, didanosine), 2′,3′-dideoxyadenosine (ddA) and of 2′,3′-didehydro-3$ ^{\prime}$-deoxythymidine (d4T, stavudine) against these late-passage viruses were shown to be enhanced with the L74→ V/I RT mutant virus as compared with the wild-type (wt) HIV-1MNisolate. Clonal analysis proved linkage of the codon 74 and codon 75 mutations to the NNRTI-specific mutations in all RT gene fragments. The nonnucleoside- and nucleoside-resistance mutation sites are separated by approximately 35 angstrom. We propose that the two sites ``communicate'' through the template-primer which is situated in the DNA-binding cleft between these two sites. Quinoxalines cause high selective pressure on HIV-1 replication in vitro; however, the implication of these findings for the treatment of HIV-1 infection has yet to be determined.</abstract><cop>United States</cop><pub>National Academy of Sciences of the United States of America</pub><pmid>8552634</pmid><doi>10.1073/pnas.93.1.34</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0027-8424 |
ispartof | Proceedings of the National Academy of Sciences - PNAS, 1996-01, Vol.93 (1), p.34-38 |
issn | 0027-8424 1091-6490 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_40173 |
source | Jstor Complete Legacy; MEDLINE; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
subjects | AIDS/HIV Amino acids Antiviral Agents - pharmacology Base Sequence Biochemistry Codons DNA Primers - chemistry Drug Resistance, Microbial Enzymes Genetic mutation HIV 1 HIV Reverse Transcriptase HIV-1 - growth & development human immunodeficiency virus 1 Inhibitory concentration 50 Molecular Sequence Data Mutation Nucleosides Quinoxalines Reverse Transcriptase Inhibitors - pharmacology RNA-Directed DNA Polymerase - genetics Selection, Genetic Virus Replication - drug effects Viruses |
title | Selective Pressure of a Quinoxaline Nonnucleoside Inhibitor of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase (RT) on HIV-1 Replication Results in the Emergence of Nucleoside RT-Inhibitor-Specific (RT Leu-74 → Val or Ile and Val-75 → Leu or Ile) HIV-1 mutants |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T21%3A39%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Selective%20Pressure%20of%20a%20Quinoxaline%20Nonnucleoside%20Inhibitor%20of%20Human%20Immunodeficiency%20Virus%20Type%201%20(HIV-1)%20Reverse%20Transcriptase%20(RT)%20on%20HIV-1%20Replication%20Results%20in%20the%20Emergence%20of%20Nucleoside%20RT-Inhibitor-Specific%20(RT%20Leu-74%20%E2%86%92%20Val%20or%20Ile%20and%20Val-75%20%E2%86%92%20Leu%20or%20Ile)%20HIV-1%20mutants&rft.jtitle=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20-%20PNAS&rft.au=Kleim,%20J%C3%B6rg-Peter&rft.date=1996-01-09&rft.volume=93&rft.issue=1&rft.spage=34&rft.epage=38&rft.pages=34-38&rft.issn=0027-8424&rft.eissn=1091-6490&rft_id=info:doi/10.1073/pnas.93.1.34&rft_dat=%3Cjstor_pubme%3E38305%3C/jstor_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17007015&rft_id=info:pmid/8552634&rft_jstor_id=38305&rfr_iscdi=true |